Neues zur Fettleber: Nomenklatur, Screening-Empfehlungen, Therapiebemühungen und andere klinisch relevante Aspekte

Die nicht-alkoholische Fettleber (NAFL) breitet sich aus: 2015 litten geschätzt fast 20 Millionen Bundesbürger an einer Fettleber, davon mehr als 3 Millionen an einer NASH und mehr als 200.000 an einer NASH-Zirrhose. Die Projektion für 2030 verheißt nichts Gutes: Es wird bevölkerungsweit eine Zunahme der NASH um 47 % und der NASH-Zirrhose um 142 % erwartet, was automatisch auch mit einer deutlichen Zunahme des HCC einhergehen dürfte [1].

Publication History

Article published online:
09 October 2023

• Literatur

• 1 Estes C, Anstee QM, Arias-Loste MT. et al. „Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030“. Journal of Hepatology 2018; 69 (04) 896-904
• 2 Kechagias S, Ernersson A, Dahlqvist O. et al. „Fast-Food-Based Hyper-Alimentation Can Induce Rapid and Profound Elevation of Serum Alanine Aminotransferase in Healthy Subjects“. Gut 2008; 57 (05) 649-654
• 3 Pontzer H, Wood BM, Raichlen DA. „Hunter-Gatherers as Models in Public Health: Hunter-Gatherer Health and Lifestyle“. Obesity Reviews 2018; 19: 24-35
• 4 Rinella ME, Lazarus JV, Ratziu V. et al. „A Multi-Society Delphi Consensus Statement on New Fatty Liver Disease Nomenclature“. Annals of Hepatology 2023; 101133
• 5 Rinella M, Charlton M. „The Globalization of Nonalcoholic Fatty Liver Disease: Prevalence and Impact on World Health“. Hepatology 2016; 64 (01) 19-22
• 6 Thursz M, Gual A, Lackner C. et al. „EASL Clinical Practice Guidelines: Management of Alcohol-Related Liver Disease“. Journal of Hepatology 2018; 69 (01) 154-181
• 7 Roeb E, Canbay A, Bantel H. et al. „Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025“. Zeitschrift für Gastroenterologie 2022; 60 (09) 1346-1421
• 8 Dietrich CG, Rau M, Geier A. „Screening for nonalcoholic fatty liver disease-when, who and how?“. World Journal of Gastroenterology 2021; 27 (35) 5803-5821
• 9 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), und European Association for the Study of Obesity (EASO). „EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease“. Journal of Hepatology 2016; 64 (06) 1388-1402
• 10 Saadeh S, Younossi ZM, Remer EM. et al. „The Utility of Radiological Imaging in Nonalcoholic Fatty Liver Disease“. Gastroenterology 2002; 123 (03) 745-750
• 11 Teufel A, Geier A, Sarrazin C. et al. „Intersektorales Management von Patienten mit unklarer Leberwerterhöhung und nichtalkoholischer Fettlebererkrankung (NAFLD)“. Zeitschrift für Gastroenterologie 2023;
• 12 Blond E, Disse E, Cuerq C. et al. „EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease in Severely Obese People: Do They Lead to over-Referral?“. Diabetologia 2017; 60 (07) 1218-1222
• 13 Sberna AL, Bouillet B, Rouland A. et al. „European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) Clinical Practice Recommendations for the Management of Non-Alcoholic Fatty Liver Diseas“. Diabetic Medicine 2018; 35 (03) 368-375
• 14 Targher G, Byrne CD, Lonardo A. et al. „Non-Alcoholic Fatty Liver Disease and Risk of Incident Cardiovascular Disease: A Meta-Analysis“. Journal of Hepatology 2016; 65 (03) 589-600
• 15 Targher G, Chonchol M, Zoppini G. et al. „Risk of Chronic Kidney Disease in Patients with Non-Alcoholic Fatty Liver Disease: Is There a Link?“. Journal of Hepatology 2011; 54 (05) 1020-1029
• 16 Wong VWS, Wong GLH, Tsang SWC. et al. „High Prevalence of Colorectal Neoplasm in Patients with Non-Alcoholic Steatohepatitis“. Gut 2011; 60 (06) 829-836
• 17 Zelber-Sagi S, Lotan R, Shlomai A. et al. „Predictors for Incidence and Remission of NAFLD in the General Population during a Seven-Year Prospective Follow-Up“. Journal of Hepatology 2012; 56 (05) 1145-1151
• 18 Romero-Gómez M, Zelber-Sagi S, Trenell M. „Treatment of NAFLD with Diet, Physical Activity and Exercise“. Journal of Hepatology 2017; 67 (04) 829-846
• 19 Mantovani A, Petracca G, Beatrice G. et al. „Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials“. Metabolites 2021; 11 (02) 73
• 20 Tacke F, Puengel T, Loomba R. et al. „An Integrated View of Anti-Inflammatory and Antifibrotic Targets for the Treatment of NASH“. Journal of Hepatology 2023; 79 (02) 552-566
• 21 Dietrich CG, Rau M, Jahn D. et al. „Changes in Drug Transport and Metabolism and Their Clinical Implications in Non-Alcoholic Fatty Liver Disease“. Expert Opinion on Drug Metabolism & Toxicology 2017; 13 (06) 625-640
• 22 Rohitash J, de la Monte SM, Ogasawara K. et al. „Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver“. Molecular Pharmaceutics 2018; 15 (07) 2621-2632
• 23 Solène M, Frost KL, Hau RK. et al. „Predicting Disruptions to Drug Pharmacokinetics and the Risk of Adverse Drug Reactions in Non-Alcoholic Steatohepatitis Patients“. Acta Pharmaceutica Sinica 2023; B13 (01) 1-28
• 24 Moore JB. „COVID-19, Childhood Obesity, and NAFLD: Colliding Pandemics“. The Lancet Gastroenterology & Hepatology 2022; 7 (06) 499-501
• 25 Kim RG, Medina SP, Magee C. et al. „Fatty Liver and the Coronavirus Disease 2019 Pandemic: Health Behaviors, Social Factors, and Telemedicine Satisfaction in Vulnerable Populations“. Hepatology Communications 2022; 6 (05) 1045-1055
• 26 López-González ÁA, Altisench B, Comas LM. et al. „Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study“. Nutrients 2022; 14 (14) 2795
• 27 Dietrich CG, Geier A, Merle U. „Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?“. World Journal of Gastroenterology 2023; 29 (02) 367-377